Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Insmed (INSM) to $144 from $126 and keeps an Equal Weight rating on the shares. Conversations with management and a key opinion leading physician have caused the firm to revise its model to better reflect the durability of brensocatib’s cash flows and the broader lifecycle potential of Insmed’s portfolio, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
- Insmed price target raised to $135 from $111 at JPMorgan
- Insmed initiated with an Outperform at William Blair
- Insmed’s Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion Opportunities
- GS, BAC, LEN: Billionaire Investor Stanley Druckenmiller Buys Bank and Housing Stocks